Marion Procter - Researcher Profile | RDL Research Database

Publications

3 shown

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart , Marion Procter , Brian Leyland‐Jones +29 more

One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (ClinicalTrials.gov...

2005 New England Journal of Medicine 5034 citations

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith , Marion Procter , Richard D. Gelber +21 more

2007 The Lancet 1503 citations

Disease-Free Survival According to Degree of <i>HER2</i> Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

Mitch Dowsett , Marion Procter , Worta McCaskill‐Stevens +11 more

Purpose To determine whether (1) immunohistochemical (IHC) HER2 status (ie, 2+ or 3+), (2) degree of fluorescence in situ hybridization (FISH) amplification according to (2a) HE...

2009 Journal of Clinical Oncology 184 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 6,721
Institution: European Institute of Oncology

External Links

Google Scholar

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.